85.8 F
Laguna Hills
Monday, Sep 26, 2022
-Advertisement-

STARTUPS & INNOVATIONS

LAUNCH

Irvine’s Ryvid Inc., an early-stage electric motorcycle company, has unveiled its first e-bike, the Anthem.

The Anthem starts at $7,800 and is said to count a range of 75 miles in eco mode or 50 miles in sport mode, with a top speed of 75 mph.

The bike’s removeable battery can be replaced for users who don’t want to wait three to six hours for the cell to charge. The Anthem comes in grey, white and gold. Deliveries for preorders are expected to begin in summer next year.

Phoenix Energy Technologies Inc., an Irvine-based energy software company, has kicked off its Carbon Manager, a cloud-based application that helps corporations monitor and report their carbon emissions.

“As concerns around global warming become more pronounced, regulators will soon require companies to disclose climate-related metrics across all scopes of their operations, including commercial buildings,” the company said in a statement. “Many stakeholders—consumers, shareholders, communities, governments, and activist groups—are also becoming more insistent that large companies disclose their ESG efforts with easy-to-understand, credible metrics.”

Carbon Manager gathers data from a corporation’s IoT devices as well as third-party sources, such as utility and weather data, and compiles it in a dashboard to help companies track and report their progress towards meeting their carbon emissions goals, according to company officials.

“We developed Carbon Manager to meet growing demand from our leading enterprise customers for a cost-effective, powerful software solution that leverages existing assets to achieve corporate sustainability goals,” Phoenix Energy CEO Glen Schrank said in a statement.

Schrank has held several CEO positions, including spots at HireRight, Essentex and Cirro.

PARTNERSHIPS

Newport Beach barware maker Snowfox Inc. has teamed up with Tustin promotional product supplier Logomark Inc. to create beer, martini, wine and highball glasses, along with ice buckets, cocktail shakers and wine carafes.

“With their focus on design and value, we believe Logomark will be a great partner for us within the promotional products industry,” Snowfox founder and CEO Cici Perrier said in a statement.

The company, founded in 2017, produces insulated, stainless-steel glass designs of wine, champagne and cocktail glasses.

“I got the idea for Snowfox from my insulated coffee tumbler, but I didn’t want to create just another tumbler for wines,” Perrier said last year. “I focused on delivering a drinking experience that’s on par with glassware, but with all the benefits of insulated stainless steel.”

NEW HIRES

Pay Ready Inc., a Huntington Beach provider of an accounts receivable software, has appointed Janis Rossi as its senior VP of marketing.

Rossi will use her experience in leading marketing teams at technology-based firms to expand and bolster the Pay Ready brand, company officials said.

Rossi, who counts over 18 years of marketing experience, previously served as the senior vice president of marketing at Wi-Fi evaluation company ROVR Score, which she co-founded last year. She also held the vice president of marketing role at Inhabit IQ, a software provider for the vacation and property management industries.

“Janis has an immense level of talent, proven success in leading marketing initiatives and establishing a brand’s identity,” Pay Ready co-founder and CEO Lynn Musil said in a statement.

Pay Ready was previously known as Debt Logic; Crunchbase estimates the company has received $1.8 million in funding to date. The company’s cloud based software platform is designed for clients to manage and track everything debt related in one place.

HEALTHCARE

Newport Beach’s AiViva Biopharma Inc., a privately owned clinical stage biotech, said it has received a U.S. patent for a product that prevent and treat fibrosis related to reproductive or digestive tract diseases.

The addition marks the 23rd approved patent for the company in the U.S., Canada, China and Japan, among other countries. The company has filed over 63 patent applications total.

“With these patents and proof of concept studies, it continues to secure our corporate position and development strategy to develop focal therapies for many diseases of significant unmet medical needs,” co-founder and CEO Diane Tang-Liu said in a statement.

She also serves as CEO of DTL BioPharma Consulting and is an adjunct professor for USC’s pharmacology and pharmaceutical sciences departments.

AiViva, founded in 2015, is developing treatments targeting neovascularization, abnormal cell proliferation and fibrosis, according to company officials. Its drug candidates are being studied to treat a variety of issues, from oncology to dermatology to ophthalmology.

ImmunogenX Inc., a Newport Beach drug developer, said the completion of its CeliacShield trial, which aimed to treat patients with celiac disease, will be published in the Gastroenterology Journal.

The study, titled “Latigultenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge,” found that ImmunogenX’s product, the Latiglutenase, protects against the negative effects of gluten consumption and breaks down about 95% of gluten in the stomach in users with celiac disease, company officials said. The research was performed at the Mayo Clinic under the direction of Principal Investigator Dr. Joseph Muray.

“We are excited by the continued success of latiglutenase as a leading therapeutic candidate for celiac disease patients as an adjunct to a gluten-free diet,” ImmunogenX CEO Jack Syage said in a statement.

“Our mission to improve the lives of celiac disease patients is inspired by members of our team who are afflicted with this disease and are the driving force to achieving success to benefit all others,” said Syage, whose prior company, Syage Technology, was bought in 2011 by France’s Safran.

ImmunogenX, founded in 2015, has raised $5 million from investors. It has also won three grants totaling an additional $6 million from different centers at the National Institutes of Health.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-